Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study

• DOI: 10.5230/jgc.2020.20.e13
• Publication Date: 2020-03-25T00:02:16Z
• Authors: Chang Min Lee; Moon-Won Yoo; Young-Gil Son; Sung Jin Oh; Jong-Han Kim; Hyoung-Il Kim; Joong-Min Park; Hoon Hur; Ye Seob Jee; Sun-Hwi Hwang; Sung-Ho Jin; Sang Eok Lee; Ji-Ho Park; Kyung Won Seo; Sungsoo Park; Chang Hyun Kim; In Ho Jeong; Han Hong Lee; Sung Il Choi; Sang-Il Lee; Chan Young Kim; In-Hwan Kim; Myoung-Won Son; Kyung Ho Pak; Sungsoo Kim; Moon-Soo Lee; Jae-Seok Min
• Keywords: Tegafur

To compare long-term disease-free survival (DFS) between patients receiving tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant chemotherapy (AC) for gastric cancer (GC).This retrospective multicenter observational study enrolled 983 who underwent curative gastrectomy with consecutive AC S-1 CAPOX stage II III GC at 27 hospitals in Korea February 2012 and December 2013. We conducted propensity score matching to reduce selection bias. Long-term oncologic outcomes, including DFS rate over 5 years (over-5yr DFS), were analyzed postoperatively.The median longest follow-up period 59.0 87.6 months, respectively. did not differ received pathologic (P=0.677) (P=0.899) GC. Moreover, hazard ratio (HR) recurrence significantly (reference) (HR, 1.846; 95% confidence interval [CI], 0.693-4.919; P=0.220) 0.942; CI, 0.664-1.337; P=0.738) After adjustment significance multivariate analysis, pT (4 vs. 1) 11.667; 1.595-85.351; P=0.016), pN (0 3) 2.788; 1.502-5.174; P=0.001), completion of planned 2.213; 1.618-3.028; P<0.001) determined as independent prognostic factors DFS.S-1 regimens show significant difference over-5yr after The pT, stage, recurrence.